AlphaQuest LLC Acquires Shares of 19,542 Integer Holdings Corporation $ITGR

Key Points

• AlphaQuest LLC has acquired 19,542 shares in Integer Holdings Corporation valued at approximately $2.3 million, highlighting ongoing institutional interest in the medical equipment provider.
• Integer Holdings Corporation reported an EPS of $1.55 for the last quarter, missing analysts' expectations slightly, although revenues were up 11.4% year-over-year.
• Institutional investors currently own 99.29% of Integer Holdings, indicating significant confidence from large investors despite recent stock fluctuations.

AlphaQuest LLC acquired a new position in Integer Holdings Corporation (NYSE:ITGR - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 19,542 shares of the medical equipment provider's stock, valued at approximately $2,306,000. AlphaQuest LLC owned approximately 0.06% of Integer at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Opal Wealth Advisors LLC purchased a new stake in Integer in the 1st quarter worth about $28,000. AdvisorNet Financial Inc purchased a new stake in Integer in the 1st quarter worth about $28,000. Bessemer Group Inc. raised its stake in shares of Integer by 73.1% during the 1st quarter. Bessemer Group Inc. now owns 296 shares of the medical equipment provider's stock worth $35,000 after purchasing an additional 125 shares in the last quarter. Sterling Capital Management LLC raised its stake in shares of Integer by 472.9% during the 4th quarter. Sterling Capital Management LLC now owns 338 shares of the medical equipment provider's stock worth $45,000 after purchasing an additional 279 shares in the last quarter. Finally, Headlands Technologies LLC raised its stake in shares of Integer by 1,234.8% during the 1st quarter. Headlands Technologies LLC now owns 1,228 shares of the medical equipment provider's stock worth $145,000 after purchasing an additional 1,136 shares in the last quarter. 99.29% of the stock is owned by hedge funds and other institutional investors.

Integer Stock Performance

Shares of NYSE:ITGR traded down $0.13 during trading on Tuesday, hitting $108.66. 223,079 shares of the stock were exchanged, compared to its average volume of 476,899. Integer Holdings Corporation has a 1-year low of $104.93 and a 1-year high of $146.36. The company has a market capitalization of $3.81 billion, a price-to-earnings ratio of 47.87, a price-to-earnings-growth ratio of 0.87 and a beta of 1.02. The company's fifty day simple moving average is $113.57 and its 200-day simple moving average is $118.67. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.18 and a current ratio of 3.41.

Integer (NYSE:ITGR - Get Free Report) last announced its quarterly earnings data on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.02). Integer had a return on equity of 12.27% and a net margin of 4.61%.The firm had revenue of $476.00 million for the quarter, compared to analyst estimates of $464.37 million. During the same period in the previous year, the business posted $1.30 EPS. Integer's revenue for the quarter was up 11.4% compared to the same quarter last year. Integer has set its FY 2025 guidance at 6.250-6.510 EPS. Sell-side analysts expect that Integer Holdings Corporation will post 6.01 EPS for the current fiscal year.

Insider Activity at Integer

In related news, Director Donald J. Spence sold 14,739 shares of the firm's stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $120.38, for a total transaction of $1,774,280.82. Following the completion of the transaction, the director owned 18,781 shares in the company, valued at $2,260,856.78. This trade represents a 43.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Martin C. Maxwell sold 8,720 shares of the firm's stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $120.56, for a total value of $1,051,283.20. Following the transaction, the director owned 22,170 shares of the company's stock, valued at $2,672,815.20. This trade represents a 28.23% decrease in their position. The disclosure for this sale can be found here. 2.16% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Wells Fargo & Company lowered their price objective on Integer from $152.00 to $132.00 and set an "overweight" rating on the stock in a report on Friday, July 25th. Truist Financial lowered their price objective on Integer from $145.00 to $137.00 and set a "buy" rating on the stock in a report on Friday, July 25th. Citigroup raised Integer from a "hold" rating to a "strong-buy" rating and increased their price objective for the company from $133.00 to $140.00 in a report on Thursday, May 22nd. Raymond James Financial lowered their price objective on Integer from $150.00 to $143.00 and set an "outperform" rating on the stock in a report on Friday, July 25th. Finally, Wall Street Zen raised Integer from a "sell" rating to a "hold" rating in a report on Monday, May 19th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $140.25.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.